Clinical Research Directory

Inclusion Criteria: * \- Native Chinese participants must be of an acceptable age to provide informed consent. * Have measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST version 1.1). * Have disease with evidence of KRAS G12C mutation * Have a histologically or cytologically proven diagnosis of locally advanced, unresectable, and/or metastatic cancer and must be appropriate candidates for study treatment. * Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Have adequate laboratory parameters. * Must be able to swallow capsules or tablets. * Estimated life expectancy ≥12 weeks Exclusion Criteria: * Have disease suitable for local therapy administered with curative intent. * Have an active fungal, bacterial, and/or active untreated viral infection, * Have a serious pre-existing medical condition(s) that would preclude participation in this study. * Have a serious cardiac condition. * Have untreated active symptomatic central neural system (CNS) malignancy or metastasis and/or carcinomatous meningitis. * Have received prior treatment with any KRAS G12C small molecule inhibitor. * Females who are pregnant or lactating. * Have a known allergic reaction against any of the components of the study drug